JP2020015733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020015733A5 JP2020015733A5 JP2019149672A JP2019149672A JP2020015733A5 JP 2020015733 A5 JP2020015733 A5 JP 2020015733A5 JP 2019149672 A JP2019149672 A JP 2019149672A JP 2019149672 A JP2019149672 A JP 2019149672A JP 2020015733 A5 JP2020015733 A5 JP 2020015733A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- polypeptide
- subject
- fgfr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 16
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 16
- 206010008723 Chondrodystrophy Diseases 0.000 claims description 8
- 208000008919 achondroplasia Diseases 0.000 claims description 8
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000055008 Matrilin Proteins Human genes 0.000 claims 1
- 108010072582 Matrilin Proteins Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000001612 chondrocyte Anatomy 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 210000004349 growth plate Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000012466 permeate Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 206010053759 Growth retardation Diseases 0.000 description 8
- 231100000001 growth retardation Toxicity 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 230000009645 skeletal growth Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 208000007326 Muenke Syndrome Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010066946 Craniofacial dysostosis Diseases 0.000 description 1
- 201000006526 Crouzon syndrome Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019149672A JP2020015733A (ja) | 2019-08-19 | 2019-08-19 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019149672A JP2020015733A (ja) | 2019-08-19 | 2019-08-19 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553175A Division JP2016506914A (ja) | 2013-01-16 | 2013-01-16 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020015733A JP2020015733A (ja) | 2020-01-30 |
| JP2020015733A5 true JP2020015733A5 (enExample) | 2020-09-10 |
Family
ID=69580027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149672A Pending JP2020015733A (ja) | 2019-08-19 | 2019-08-19 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2020015733A (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110272900B (zh) * | 2019-04-19 | 2024-03-26 | 中国人民解放军陆军军医大学 | 用于制备骨骼发育异常猪模型的sgRNA及其应用 |
| WO2024194300A1 (en) * | 2023-03-20 | 2024-09-26 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0833620T3 (da) * | 1995-06-12 | 2003-01-13 | Yeda Res & Dev | FGFR3, en markør for mesenkymale progenitorceller |
| IL159177A0 (en) * | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| JP2003104908A (ja) * | 2001-09-28 | 2003-04-09 | Ichikazu Nakao | 軟骨無形成症治療剤 |
| BRPI0203172B8 (pt) * | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| IL156495A0 (en) * | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| ATE533853T1 (de) * | 2004-02-24 | 2011-12-15 | Allergan Inc | Botulinumtoxin-screening-assays |
| EP2083081A1 (en) * | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| WO2008133873A2 (en) * | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| CA2823066A1 (en) * | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
-
2019
- 2019-08-19 JP JP2019149672A patent/JP2020015733A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7272663B2 (ja) | インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法 | |
| US20240226243A9 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| DE69433820T2 (de) | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten | |
| KR101673654B1 (ko) | 융합 단백질 TNFR:Fc의 안정한 제약 액체 제제 | |
| US20240226236A9 (en) | Nerve growth factor fusion protein, preparation method and use thereof | |
| US20230241168A1 (en) | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof | |
| DK2633865T3 (en) | USE OF INTERLEUKIN-22 IN THE TREATMENT OF VIRAL HEPATITIS | |
| US20080031875A1 (en) | Treatment method | |
| JP2010518079A5 (enExample) | ||
| BRPI0622256A2 (pt) | formulações estáveis adequadas para administração subcutánea compreendendo moléculas de ctla4ig | |
| JP2022512541A (ja) | Ｐｄ－１系キメラタンパク質を含む併用療法 | |
| CA3128113A1 (en) | Pharmaceutical taci-fc fusion protein formulation | |
| JP2016506914A5 (enExample) | ||
| JP2016506912A5 (enExample) | ||
| AU2024204870A1 (en) | Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin | |
| JP2020015733A5 (enExample) | ||
| EP3169348B1 (en) | Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases | |
| JP6480154B2 (ja) | エタネルセプトの凍結乾燥製剤 | |
| AU2019364063B2 (en) | Pharmaceutical composition for treating aplastic anemia | |
| EP1596879B1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| Weaver | Efficacy and safety of the anti-TNF biologic agents | |
| KR20250048156A (ko) | 제제에 접합된 인슐린 유사 성장 인자 1 수용체 리간드를 사용한 자가면역 질환의 치료 | |
| JP7606173B2 (ja) | Ｉ型インターフェロンの中和型Ｆｃ融合タンパク質及びその使用 | |
| HK40059370A (en) | Pharmaceutical composition for treating aplastic anemia | |
| HK40012327A (en) | Peptides for treating sjogren's syndrome |